These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15944112)

  • 1. Immunoadsorption therapy and complement activation.
    Pták J; Lochman J
    Transfus Apher Sci; 2005 Jun; 32(3):263-7. PubMed ID: 15944112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of selected hematologic parameters during long-term immunoadsorption therapy.
    Pták J
    Transfus Apher Sci; 2005 Nov; 33(3):299-304. PubMed ID: 16203175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of aortic reconstruction and collagen impregnation of Dacron prostheses on the complement system.
    De Mol Van Otterloo JC; Van Bockel JH; Ponfoort ED; Brommer EJ; Hermans J; Daha MR
    J Vasc Surg; 1992 Nov; 16(5):774-83. PubMed ID: 1433666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total hemolytic complement (CH50) and its fractions C3 and C4 in the sera of patients with localized juvenile periodontitis.
    Anil S; Beena VT; Remani P; Mysore J; Vijayakumar T
    Ann Dent; 1993; 52(1):18-20. PubMed ID: 8323245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of aging on complement activity (CH50) and complement protein levels.
    Nagaki K; Hiramatsu S; Inai S; Sasaki A
    J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunology of chronic generalized periodontitis. 2. Estimation of total hemolytic complement (CH 50) and its fractions C3 and C4.
    Anil S; Beena VT; Remani P; Haseenabeevi M; Vijayakumar T
    Indian J Dent Res; 1991; 2(3-4):35-9. PubMed ID: 1821159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of myasthenia gravis by immunoadsorption of plasma.
    Grob D; Simpson D; Mitsumoto H; Hoch B; Mokhtarian F; Bender A; Greenberg M; Koo A; Nakayama S
    Neurology; 1995 Feb; 45(2):338-44. PubMed ID: 7854536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of patients with premalignant and malignant lesions of the oral cavity.
    Rajendran R; Remani P; Vijayakumar T; Vasudevan DM
    Ann Dent; 1990; 49(1):36-8, 51. PubMed ID: 2346298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
    Pták J
    Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
    Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D
    Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-ionic iodinated dimeric versus monomeric X-ray contrast media: effects on complement factors in vivo].
    Böhm I; Speck U; Schild H
    Rofo; 2006 Mar; 178(3):306-12. PubMed ID: 16508838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation during CAPD.
    Young GA; Kendall S; Brownjohn AM
    Nephrol Dial Transplant; 1993; 8(12):1372-5. PubMed ID: 8159307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The difference between serum and plasma complement activity in primary renal disease.
    Akagaki Y; Fujiwara Y; Nakanishi I; Orita Y; Ando A; Abe H; Kitamura H; Nagaki K; Inai S
    Clin Nephrol; 1980 Aug; 14(2):75-80. PubMed ID: 7408259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in plasma levels of complement in patients with acute ischemic stroke.
    Cojocaru IM; Cojocaru M; Tănăsescu R; Burcin C; Atanasiu AN; Petrescu AM; Mitu AC; Iliescu I; Dumitrescu L
    Rom J Intern Med; 2008; 46(1):77-80. PubMed ID: 19157274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation in patients with primary antiphospholipid syndrome.
    Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
    Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of diabetic patients with periodontitis.
    Anil S; Remani P; Vijayakumar T; Joseph PA
    J Periodontol; 1990 Jan; 61(1):27-9. PubMed ID: 2107297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation following multiple injuries.
    Fosse E; Mollnes TE; Aasen AO; Trumpy JH; Stokke T
    Acta Chir Scand; 1987; 153(5-6):325-30. PubMed ID: 3499041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum complement 3 (C3) and complement 4 (C4) level in febrile neutropenia patients at Dr. Kariadi Hospital, Semarang and Dr. Moewardi Hospital, Surakarta.
    Maryono S; Guntur A; Suharti C
    Acta Med Indones; 2008 Jan; 40(1):14-8. PubMed ID: 18326894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.